Micrograph of hepatocellular carcinoma. Liver biopsy. Trichrome stain. © Nephron

Roche AG said on Friday that its PD-L1 blocker Tecentriq plus its VEFG blocker Avastin improved progression-free survival versus sorafinib in a pivotal study in hepatocellular carcinoma (HCC) patients.

NCI
Azeria Therapeutics Ltd (Cambridge, UK) has raised a £32m (€37.3m) in a Series B financing led by Syncona Ltd contributing £29.5m (€34.4m).
© Nattanan Kanchanaprat

GHO Capital raises €975m in largest ever European private equity healthcare fund.
   

BIOCOM AG

Europe’s largest partnering event, the BIO-Europe, hit another visitor record on the occasion of its 25th anniversary in Hamburg.

© Zelluna

Zelluna Immunotherapy and Glycostem Therapeutics have partnered to develop allogeneic TCR-NK therapies.

GalXC platform. © Dicerna

Danish Novo Nordisk A/S has secured access to Dicerna Inc’s GalXC RNAi technology in a R&D deal worth US$225m upfront over three years comprising 30 liver targets.

© Dr Graham Beards at en.wikipedia, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=25206097

The EU has made poor progress combatting antimicrobial resistance, a report from the European Court of Auditors (ECA) warns. Innovators need to be supported, urges the BEAM Alliance.
 
 

© Cellectis SA

Researchers at French-US allogeneic CAR-T cell developer Cellectis SA have designed an engineered CAR-T cell that secretes IL-12 upon contact with tumour cells.

ADC structure. In ATACs the cytotoxic payload is alpha-amanitin. © International Journal of Molecular Sciences, doi: 10.3390/ijms17040561
JO  - s

Magenta Therapeutics has exercised the option to licence Heidelberg Pharma AG’s anti-CD45-Antibody Targeted Amanitin Conjugate (ATAC).

Geralt / Pixabay

Swiss-German biotech Vaximm is teaming up with Tokyo-based AI specialist NEC to advance personalised neoantigen cancer vaccines.